N/A N=66 Complex Sleep Apnea Syndrome (CompSAS) Resolution Study
Complex Sleep Apnea Syndrome
Primary: Apnea-hypopnea Index (AHI) Per Polysomnography (PSG) at the End of Treatment Period — 4.4; 9.9 AHI (events/hour)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Combination Therapy to Treat Sleep Apnea
Sleep Apnea, Obstructive
Primary: Model Prediction of Absence/Presence of OSA: Ventilation That Causes an Arousal From Sleep (Varousal) — 5.7; 5.2 L/min — p=0.05
Phase 2 N=50 Effects of Treatment of Sleep Apnea on Metabolic Syndrome
Impaired Glucose Tolerance · Obstructive Sleep Apnea
Primary: Number of Subjects With Normalization of Impaired Glucose Tolerance (IGT) — 7; 5 subjects — p=0.57
N/A N=169 Sleep Apnea Intervention for Cardiovascular Disease Reduction
Obstructive Sleep Apnea
Primary: Change From Baseline in 24-hour Blood Pressure at Months 6 and 12 by Pooled Arms — 1.82; 1.06; 0.59; -0.73 mmHg
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001
N/A N=32 Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 2.4 events per hour
N/A N=9 Long QT Syndrome and Sleep Apnea
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
N/A N=25 Servo-Ventilation In-lab PSG Evaluation
Sleep Apnea Syndromes
Primary: Average Apnea Hypopnea Index Among Different Polysomnography Devices. — 18.4; 25.4; 24.1; 19.2 events per hour
N/A N=34 Positive Airway Pressure Program
Sleep Apnea, Obstructive
Primary: Participant Providing Feedback — 26 Participants
N/A N=29 Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients
Cheyne-Stokes Respiration · Sleep Apnea, Central
Primary: Apnea/Hypopnea Index (AHI) — 55; 37; 12 Apnea-Hypopnea events per hour
N/A N=29 Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk
Sleep Apnea Syndromes
Primary: Fat Mass (% of Total Body Mass) — 40.0; 37.7; 38.7; 38.6 percentage of total body mass
N/A N=23 Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Down Syndrome · Obstructive Sleep Apnea Syndrome
Primary: Change in Epworth Sleepiness Scale From Baseline to End of Study — -1; -0.5; 1 units on a scale
Phase 4 N=14 Sleep and Breathing in the General Population - Chemical Stimuli
Sleep-disordered Breathing
Primary: The Central Apnea-hypopnea Index — 14.1; 29.9 events per hour
N/A N=104 Lifestyle Modification Program to Treat Obstructive Sleep Apnea Patients
Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index (AHI) at One Year — 35.3; 39.6 events per hour
Phase 3 N=1,105 Apnea Positive Pressure Long-Term Efficacy Study
Lung Diseases · Sleep Apnea Syndromes · Sleep
Primary: Effect of CPAP on Neurocognitive Function: E/F Function- SWMT-OMD — 0.035; -0.074; 0.072; 0.018 score on a scale — p=0.0074
N/A N=25 The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea
Sleep Apnea
Primary: Flow Mediated Dilation — 5.7; 9.5; 7.3 percentage change of vessel diamter — p=0.02
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
N/A N=150 Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP
Obstructive Sleep Apnea
Primary: Change in Total Sleep Time Before and After CPAP Therapy in Obstructive Sleep Apnea Patients — 29 minutes — p=<0.05
N/A N=45 Understanding the Sleep Apnea/Insomnia Interaction
Sleep Apnea Syndromes · Sleep Initiation and Maintenance Disorders
Primary: Insomnia Severity Index Score — -8.2; -7.33; -6.27 score on a scale — p=0.8
N/A N=144 Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness
Sleep Apnea, Obstructive
Primary: Subjective Sleepiness — 11.8; 10.2; 9.9 units on a scale
Phase 2 N=20 Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
OSA · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 17.1; 32.7; 26; 23.6 events/hour of sleep
N/A N=39 Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk
Diabetes · Sleep Apnea
Primary: Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2 — -794.2; 482.7 (mg/dL)*min — p=0.03
N/A N=129 Metabolic Impact of Intermittent CPAP
Obstructive Sleep Apnea
Primary: Concentration of Plasma Free Fatty Acids (FFA, mmol/L) — 0.47; 0.51 mmol/L
N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
N/A N=184 Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy
Sleep Apnea · Diabetes
Primary: Change in Continuous Glucose Monitoring System Standard Deviation — 0.8; 1.1 mg/dL
Phase 2 N=13 DAW1033B2 in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 33; 20.4 events/hour of sleep — p=0.47
Early Phase 1 N=63 Respiratory and Autonomic Plasticity Following Intermittent Hypoxia
Sleep Apnea Syndromes
Primary: Ventilation (Aim 1) — 1.19; 1.14; 1.35; 1.16 fraction of baseline — p=0.001
N/A N=25 Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Objective Sleep Parameters
Phase 3 N=225 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack
Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants
N/A N=15 The Effects of Trazodone on Sleep Apnea Severity
Sleep Apnea, Obstructive
Primary: Apnea-Hypopnea Index — 38.7; 28.5 events/hour